Paper Details

  1. Home
  2. Paper Details

A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.

Author: BlierPierre, GoodmanWayne K, MandokiMiguel, MurphyTanya K, ShapiraNathan A, WardHerbert E, YangMark C K

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study evaluated the effectiveness of adding olanzapine to fluoxetine for treating obsessive-compulsive disorder (OCD). The results showed no additional benefit for adding olanzapine compared to extending the fluoxetine monotherapy trial.
Paper Details　
Original Abstract of the Article :
BACKGROUND: One of the few combination approaches to the treatment of obsessive-compulsive disorder (OCD) with encouraging support is the addition of an antipsychotic to a serotonin reuptake inhibitor. METHODS: The study consisted of a 6-week, placebo-controlled addition of olanzapine 5-10 mg (6.1 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15023585

データ提供：米国国立医学図書館（NLM）

Olanzapine for Fluoxetine-Refractory Obsessive-Compulsive Disorder: A Double-Blind Trial

Obsessive-compulsive disorder (OCD) is a mental health condition characterized by intrusive thoughts and repetitive behaviors. This study investigated the effectiveness of adding olanzapine, an antipsychotic medication, to fluoxetine treatment in patients with OCD who did not respond adequately to fluoxetine alone. The researchers conducted a double-blind, placebo-controlled trial involving 44 patients with OCD who had previously received 8 weeks of fluoxetine treatment.

Olanzapine: A Quest for Additional Benefit in OCD

The study found that both the fluoxetine-plus-olanzapine and fluoxetine-plus-placebo groups showed significant improvements in OCD symptoms over 6 weeks. However, there was no significant difference between the two groups, suggesting that adding olanzapine did not provide an additional benefit beyond extending the fluoxetine monotherapy trial.

Navigating OCD Treatment: A Journey of Personalized Approaches

This research provides valuable insights into the treatment of OCD. The study's findings suggest that adding olanzapine to fluoxetine may not be necessary for patients who have not responded adequately to fluoxetine alone.

Dr.Camel's Conclusion

This study emphasizes the importance of individualized treatment approaches for OCD. The findings suggest that while olanzapine may not offer additional benefits in patients who are not responding well to fluoxetine, other treatment options may be more effective.

Date :
  1. Date Completed 2004-05-27
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

15023585

DOI: Digital Object Identifier

S0006322303012095

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.